Nicole Fowler

Dec 4, 2024 | agsjournals.onlinelibrary.wiley.com | Carolyn DiGuiseppi |Linda Hill |Nicole Fowler |Rachel Johnson

CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported. Supporting Information Filename Description jgs19293-sup-0001-Supplemental_Materials.pdfPDF document, 279.8 KB Supplemental Figure 1. CONSORT 2010 flow diagram. Supplemental Table 1. Longitudinal outcomes in the AUTO study. Supplemental Table 2.

Jul 16, 2024 | onlinelibrary.wiley.com | Anu Sharma |Humzah A. Quereshy |Claudia Cabrera |Nicole Fowler

1 INTRODUCTION Concurrent chemoradiation is commonly used to definitively treat locally advanced head and neck squamous cell cancers (HNSCC).1, 2 At many institutions, the standard of care is to conduct a post-treatment Fluorine-18-Fluorodeoxyglucose (18F-FDG) Positron-Emission Tomography/Computed Tomography (PET/CT) 3 months following completion of concurrent chemoradiation as a measure of response to therapy.3, 4 18F-FDG is an analog of glucose; therefore, its uptake in lymph nodes suggests...

Aug 2, 2023 | neurologylive.com | Nicole Fowler

WATCH TIME: 3 minutes"The most current sort of way that we’ve been doing diagnosis of patients has been clinical, both history, physical, and then a battery of neuropsychological tests. Maybe with some imaging, but that’s expensive.

Jul 20, 2023 | neurologylive.com | Nicole Fowler

WATCH TIME: 4 minutesWith the emergence of novel therapeutics, including new amyloid-targeting agents, the importance of early identification of people at risk of developing Alzheimer disease (AD) is more critical than ever. The development of feasible, acceptable, and scalable ways to identify early cognitive impairment in the primary care setting is essential, considering these are areas that will first encounter patients presenting with cognitive issues.